And it is the potential mechanism of the Wnt pathway on the PD-1/PD-L1 pathway that makes non-small cell lung cancer (NSCLC) patients somewhat resistant to immune checkpoint inhibitors (ICIs), so it seems that the combination of Wnt inhibitors and ICIs could be a new option for the treatment of LC patients (78). This evidence concerns the gene CD274 and laryngotracheoesophageal cleft.